Idioma:

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Colao, Annamaria ; Petersenn, Stephan ; Newell-Price, John ; Findling, James W ; Gu, Feng ; Maldonado, Mario ; Schoenherr, Ulrike ; Dipl.-Biol ; Mills, David ; Salgado, Luiz Roberto ; Biller, Beverly M.K

The New England journal of medicine, 2012-03, Vol.366 (10), p.914-924 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Autor: Colao, Annamaria ; Petersenn, Stephan ; Newell-Price, John ; Findling, James W ; Gu, Feng ; Maldonado, Mario ; Schoenherr, Ulrike ; Dipl.-Biol ; Mills, David ; Salgado, Luiz Roberto ; Biller, Beverly M.K
Assuntos: Adolescent ; Adrenals. Adrenal axis. Renin-angiotensin system (diseases) ; Adrenocorticotropic hormone ; Adrenocorticotropic Hormone - blood ; Adult ; Aged ; Biological and medical sciences ; Child ; Clinical trials ; Cushing syndrome ; Cushing's disease ; Dosage and administration ; Dose-response relationship (Biochemistry) ; Double-Blind Method ; Drug therapy ; Drugs ; Endocrinopathies ; Female ; General aspects ; Hemoglobin ; Humans ; Hydrocortisone ; Hydrocortisone - analysis ; Hydrocortisone - blood ; Hydrocortisone - urine ; Hyperglycemia ; Life Sciences ; Male ; Medical sciences ; Middle Aged ; Morbidity ; Mortality ; Nervous system diseases ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Orphan drugs ; Patients ; Pituitary ; Pituitary ACTH Hypersecretion - blood ; Pituitary ACTH Hypersecretion - drug therapy ; Pituitary ACTH Hypersecretion - urine ; Pituitary gland ; Product/Service Evaluations ; Recurrence ; Saliva - chemistry ; Somatostatin ; Somatostatin - adverse effects ; Somatostatin - analogs & derivatives ; Somatostatin - therapeutic use ; Surgery ; Young Adult
É parte de: The New England journal of medicine, 2012-03, Vol.366 (10), p.914-924
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
Descrição: This study assessed pasireotide, a somatostatin-receptor–binding analogue, at two dose levels for the treatment of Cushing's disease. The median urinary free cortisol level decreased by about 50% by month 2 and remained stable in the higher-dose and lower-dose groups. Cushing's disease is a rare disorder of chronic hypercortisolism due to a corticotropin-secreting pituitary adenoma. The disorder is associated with central obesity, osteoporosis, arterial hypertension, insulin resistance, glucose intolerance, diabetes mellitus, dyslipidemia, cardiovascular disease, and increased mortality. 1 – 5 Transsphenoidal surgery is the primary therapy in most patients, with remission rates of 65 to 90% when an expert pituitary surgeon operates. 6 However, remission definitions vary, and relapse occurs in up to 30% of patients. Second-line options include repeat pituitary surgery, radiation therapy, bilateral adrenalectomy, and medical therapy. However, current medical treatments have not been tested in large prospective, randomized trials. Corticotroph . . .
Editor: Waltham, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Este item no Dedalus

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Colao, Annamaria ; Petersenn, Stephan ; Newell-Price, John ; Findling, James W ; Gu, Feng ; Maldonado, Mario ; Schoenherr, Ulrike ; Dipl.-Biol ; Mills, David ; Salgado, Luiz Roberto ; Biller, Beverly M.K

Waltham, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.